Cancer drug dose test halted before starting
NCT ID NCT02315157
Summary
This early-stage study aimed to find the safest and most effective dose of the chemotherapy drug bendamustine for people with multiple myeloma who had been treated before. Researchers planned to give increasing doses to small groups of patients to see how much they could tolerate. The study was withdrawn before any patients were enrolled.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Thomas Jefferson University
Philadelphia, Pennsylvania, 19107, United States
Conditions
Explore the condition pages connected to this study.